To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.
This bill requires the Government Accountability Office to study and report on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers.
Actions
Jul 1, 2021
Referred to the Subcommittee on Health.
Jun 30, 2021
Referred to the House Committee on Energy and Commerce.